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SUMMARY 
 
Background: The regular use of simple analgesics in addition to opioids such as paracetamol (or 
acetaminophen) is recommended for persistent pain to enhance analgesia. Few studies have 
examined the frequency and doses of paracetamol among people with chronic non-cancer pain 
including use above the recommended maximum daily dose. Aims: To assess (i) the prevalence of 
paracetamol use among people with chronic non-cancer pain prescribed opioids, (ii) assess the 
prevalence of paracetamol use above the recommended maximum daily dose and (iii) assess 
correlates of people who used paracetamol above the recommended maximum daily dose including: 
age, gender, income, education, pain severity and interference, use of paracetamol/opioid 
combination analgesics, total opioid dose, depression, anxiety, pain self-efficacy or comorbid 
substance use, among people prescribed opioids for chronic non-cancer pain. Methods: This study 
draws on baseline data collected for the Pain and Opioids IN Treatment (POINT) study and utilises 
data from 962 interviews and medication diaries. The POINT study is national prospective cohort of 
people with chronic non-cancer pain prescribed opioids. Participants were recruited from randomly 
selected pharmacies across Australia. Results: Sixty-three per cent of the participants had used 
paracetamol in the past week (95% CI = 59.7–65.8). Among the paracetamol users 22% (95% CI = 
19.3–24.6) had used paracetamol/opioid combination analgesics and 4.8% (95% CI = 3.6–6.3) had 
used paracetamol above the recommended maximum daily dose (i.e. > 4000 mg/day). Following 
binomial logistic regression (v2 = 25.98, df = 10, p = 0.004), people who had taken above the 
recommended maximum daily dose were less likely to have low income (AOR = 0.52, 95% CI = 0.27–
0.99), more likely to use paracetamol/opioid combination analgesics (AOR = 2.01, 95% CI = 1.02–
3.98) and more likely to take a higher opioid dose (AOR = 1.00, 95% CI = 1.00–1.01). Conclusion: The 
majority of people with chronic non-cancer pain prescribed opioids report using paracetamol 
appropriately. High income, use of paracetamol/opioid combination analgesics and higher opioid 
dose were independently associated with paracetamol use above the recommended maximum daily 
dose. 
 
Introduction 
Chronic pain is a highly prevalent condition that imposes a considerable burden on individuals and 
the wider community. In Europe and the USA, the prevalence of chronic pain is approximately 19% 
(1) and 31% (2) respectively. In Australia, chronic pain affects approximately 17% of women and 20% 
of men (3). There have been dramatic increases in the use of prescription opioids, for example from 
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1992 to 2007, opioid prescriptions in Australia increased by 300% (4). Despite the common use of 
opioids for chronic non-cancer pain (CNCP), qualitative and quantitative reviews of opioid use in 
chronic pain report that opioids may reduce pain by 30%, or 2–3 points on a 10 point analogue visual 
scale (5–7), suggesting that opioid medications alone may not provide adequate pain relief. 
Paracetamol is relatively inexpensive, readily available and has minimal risk of adverse events when 
used at recommended doses (8,9). Use of paracetamol in conjunction with opioids can enhance 
analgesia (9,10) and the World Health Organization’s (WHO) three-step pain ladder (though 
originally developed for cancer pain, the recommendations are considered appropriate for other 
types of pain) (11) recommends that at Step 2 and 3, round-the-clock dosing of both opioid 
medication and adjuvant medications that enhance analgesia (including paracetamol) be used (12). 
However, use of paracetamol above the recommended maximum daily dose (greater than 4000 
mg/day) can cause adverse effects (13–15). Although paracetamol is commonly used in practice, to 
date, there is a lack of literature describing the frequency of use, the range of dosages and frequency 
of inappropriate use in people with CNCP. 
Recently, the United States Food and Drug Administration (FDA) have limited the amount of 
paracetamol per tablet in paracetamol/opioid combination analgesics to 325 mg instead of 500 mg. 
This change has been made because studies on paracetamol overdoses in the USA have reported 
that almost half of paracetamol overdoses are unintentional and a large proportion of overdoses 
occur from combination products (16, 17). Studies have also reported that 19% of people in the USA 
prescribed paracetamol/ opioid combination analgesics were at risk of liver toxicity because of 
prescriptions exceeding the maximum recommended daily dose of paracetamol (13) and that 
prescriptions exceeding 4000 mg/day accounted for 6–8% of all paracetamol/opioid combination 
prescriptions (13,18). Literature on the associations of paracetamol and other over the counter 
medication use, report that those who exceed the maximum daily dose are more likely to have 
current pain, to be taking opioids or be prescribed more types of analgesics, to have depression and 
anxiety and to currently smoke cigarettes (19–21). 
To date, there has been minimal literature on paracetamol use and the subset of inappropriate 
paracetamol use in people with CNCP prescribed opioids. Specifically, this study aims to examine: (i) 
the prevalence of paracetamol use in people with CNCP prescribed opioids, as well as the range of 
dosages and the types of combination products used (ii) the prevalence of paracetamol use above 
the recommended maximum daily dose and (iii) whether demographic characteristics, pain severity 
and interference with daily activities, use of paracetamol/opioid combination analgesics, total opioid 
dose, mental health and comorbid substance use, are associated with paracetamol use above the 
recommended maximum daily dose. 
 
Methods 
Study Design 
This paper uses data from the Pain and Opioids IN Treatment (POINT) study. The POINT study is a 
national prospective cohort that aims to follow 1500 people with CNCP prescribed opioids over a 24-
month period. For a detailed description of the POINT study protocol, see Campbell et al. (22). In 
brief, participants were recruited from randomly selected Australian pharmacies. Eligible 
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participants had chronic pain (defined as persistent pain for 3 months or more), were currently 
prescribed opioids for at least 6 weeks, were not currently suffering from cancer, and were not 
currently undergoing opioid substitution treatment for the management of opioid dependence 
developed through heroin use. 
The major aims of the POINT study are to examine the natural history of prescribed opioid use; 
examine the predictors of adverse events; and identify factors that predict poor self-reported pain 
relief and other outcomes. The study was approved by the Human Research Ethics Committee of the 
University of New South Wales (HREC reference: # HC12149). 
 
Recruitment 
Research staff randomly contacted 5532 pharmacies (93% of pharmacies across Australia) for 
expressions of interest to recruit for the study, 1868 (34%) agreed to help with recruitment and of 
those pharmacies that agreed to recruit, 480 (26%) actively recruited. Pharmacists were asked to 
hand out flyers to customers who came into the pharmacy to fill a Schedule 8 opioid prescription 
and interested customers then left their details for contact by the research team to be made. 
Schedule 8 opioids are opioids subject to strict regulatory controls regarding their manufacture, 
supply, distribution, possession and use (23). These opioids included: buprenorphine, codeine (30 
mg codeine tablets or codeine linctus), fentanyl, hydromorphone, morphine and oxycodone. 
From this referral method, 2318 people expressed an interest, 1262 (54%) participated in the study, 
310 (13%) were ineligible, 343 (15%) refused to participate and 403 (17%) could not be contacted. Of 
those who were ineligible, 132 (43%) felt they were too unwell to participate, 9 (3%) did not speak 
English, 105 (34%) had not been prescribed opioids for 6 weeks, 40 (13%) were suffering from 
cancer, six (2%) were receiving opioid substitution treatment for heroin dependence and 18 (6%) did 
not meet study criteria for suffering from chronic pain (defined as pain lasting 3 months or longer). 
Of the participants who completed the baseline interview and had adequate time to complete and 
return the study pack, 962 (74%) returned the medication diary. 
 
Medication use 
Daily dose and days of use in the past week for all prescribed and non-prescribed medications were 
collected via a 1 week self-complete medication diary, which participants were asked to complete in 
the same week that they completed the phone and baseline self-report survey. A total daily 
paracetamol dose was calculated from the medication diary for each person by adding the dose of 
paracetamol present in all paracetamol-containing medications (including combination products) for 
each day in the last week. Use above 4000 mg on any day was considered use above the 
recommended maximum daily dose (24). 
A protocol for converting the mean daily opioid doses to oral morphine equivalent dose was 
constructed for the POINT study (see Appendix 1) (25). A mean daily dose was calculated for each 
opioid medication by dividing the total weekly dose by the number of days of use. The mean daily 
doses for each of the opioids were converted to oral morphine equivalent doses (in milligram 
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morphine equivalent units). The oral morphine equivalent doses were then added together to create 
a total daily opioid dose. Dose conversion ratios were cross-checked from the Therapeutic 
Guidelines (26), Australian Medicines Handbook (27) and a consensus document developed by the 
faculty of Pain Medicine of the Australian and New Zealand College of Anaesthetists (FPMANZCA). 
Where there was non-concordance between the three references, precedence was given to 
recommendations by the Therapeutic Guidelines and in the case of methadone, Walker et al. (28) 
was used for calculating oral morphine equivalent doses. 
 
Covariates 
Participant demographics were self-report variables obtained from the baseline phone interview and 
included age, gender, education, chronic pain condition and current income. Income was reported 
as greater than or less than/equal to $399/week, which is approximately equivalent to the weekly 
allowance of government pensions. Also used in the analysis were baseline interview variables from 
the: Brief Pain Inventory (BPI) for pain severity and interference (29); Patient Health Questionnaire 9 
item (PHQ9) scale for Depression (30,31); Generalized Anxiety Disorder 7 item (GAD-7) scale (32); 
the Pain Self-Efficacy Questionnaire (PSEQ) (33) and the Opioid-Related Behaviours in Treatment 
(ORBIT) scale (34). 
 
Pain severity and interference 
The BPI measures pain severity using an 11 point scale and participants rate the worst, least and 
average pain experienced in the last week as well as current pain level. These measures are 
presented individually and as a total mean pain severity score. The BPI also measures the degree of 
relief provided by all medications and treatments provided in the last week as a percentage. 
Participants also rate the level of interference pain causes to activities on an 11 point scale; including 
general activity, mood, walking ability, work, relationships, sleep and enjoyment of life. A mean 
interference score was then calculated for participants who answered 50% or more of the questions 
(29,35,36). 
 
Symptoms of anxiety and depression 
PHQ-9 and GAD-7 measure the severity of the 9 DSM-V depressive symptoms and 7 symptoms of 
anxiety over the last 2 weeks. The severity of depression or anxiety was calculated by the sum of 
scores for each response to a symptom of depression or anxiety. PHQ-9 and GAD-7 scores greater 
than 10 meet criteria for moderate to severe depression or anxiety symptoms (30,31). 
 
Pain self-efficacy questionnaire 
All participants were asked 10 questions regarding their confidence to do a variety of activities 
‘despite their pain’. The activities included physical activities (completing chores, working, becoming 
more active and socialising) as well as emotional experiences (accomplishing goals, coping with pain 
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and enjoying things). These questions were scored on a 7 point scale where 0 means ‘not at all 
confident’ and 6 means ‘completely confident’. A total score is calculated by the sum of these scores 
(33). 
 
Aberrant opioid-related behaviours 
All participants were asked 10 questions regarding aberrant opioid-related behaviours over the 
preceding 3 months. These were scored dichotomously and added to give a total score using the 
Opioid-Related Behaviours in Treatment (ORBIT) scale (e.g. ‘Over the past 3 months, I have asked my 
doctor for an increase in my prescribed dose’). The ORBIT scale was developed for use among 
Australian people receiving opioids for pain or opioid dependence in both clinical and research 
settings. The scale has demonstrated strong internal consistency (Cronbach’s alpha = 0.85) (34). 
 
Statistical analysis 
Analyses were conducted using IBM SPSS statistics version 22 (SPSS, Inc., Chicago, IL, USA). At 
bivariate level, continuous variables were compared with paracetamol use below and above the 
recommended maximum daily dose using the independent samples t-test and Mann–Whitney U for 
all non-normally distributed variables. Categorical variables were compared using odds ratios (ORs). 
All significance tests were two-sided and conducted at a 0.05 significance level. A logistic regression 
analysis was used to examine predictors of paracetamol use in excess of maximum recommended 
daily doses. Variables that were included in the model were demographic variables (sex and age) and 
all variables in the bivariate analysis that had a p-value less than 0.25. Linearity assumption tests (37) 
were also conducted for all continuous variables in the model using the BoxTidwell (1962) procedure 
(38). 
 
Results 
Demographics and health characteristics 
The mean age of the participants was 59 years (SD 13.3) and ranged from 21 to 94 years. Over half 
were female (57%, 95% CI = 53.4–59.7), about one-third 
(34%, 95% CI = 31.4–37.4) were retired, 47% (95% 
CI = 43.6–50.2) were unemployed and 60% (95% CI = 57.3–63.4) had a weekly income of $399 or 
less. Almost two-thirds (61%, 95% CI = 58.2–63.4) reported changing their employment in some way 
because of their pain condition. Participants had been living with chronic pain for a median of 10 
years (ranging between 0 and 72 years) and 73% (95% CI = 70.6–76.2) have had two or more 
problematic chronic pain conditions in the last 12 months. In addition to experiencing chronic pain, 
51% (95% CI = 48.1–54.4) of participants reported having an additional problematic physical 
condition in the last 12 months, for example, problems relating to stroke, heart attack, sleep 
apnoea, heart disease, hypertension, chronic respiratory diseases, diabetes, HIV, epilepsy, seizures 
and cancer. Furthermore, 44% (95% CI = 41.1–47.3) met criteria for current moderate to severe 
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depression and 22% (95% CI = 18.8–24.0) met criteria for current moderate to severe generalised 
anxiety disorder (Table 1). 
  
Medication use 
The most commonly used opioids were oxycodone (56%, 95% CI = 52.7–58.9) and buprenorphine 
(21%, 95% CI = 18.8–24.0; Table 2). In addition, 
25% (95% CI = 22.5–28.0) were taking another opioid, with codeine combinations (17%, 95% CI = 
14.9–19.7) the most common. The median total daily opioid dose was 68 mg (IQR = 106 mg) and 
ranged from 0 mg to 800 mg. In addition to the opioids, over half of all participants (56%, 95% CI = 
52.3–58.6) had taken antidepressants and a quarter had taken antiepileptic (27%, 95% CI = 24.0–
29.6) or benzodiazepine medications (26%, 95% CI = 23.6–29.2) in the last week. 
In addition to prescribed medications, 64% (95% CI = 60.5–66.7) of participants also reported using 
over the counter strength analgesic medications in the last week, with the most prevalent being 
medications containing paracetamol (50%, 95% CI = 47.3– 53.6). When prescription only forms of 
paracetamol were included [for example, paracetamol/codeine combinations containing ≥ 30 mg of 
codeine per tablet (23)], 63% (95% CI = 59.7–65.8) had taken some form of paracetamol in the last 
week. 
The most common form of paracetamol was paracetamol as the only active ingredient (47%, 95% CI 
= 43.6–49.9; Figure 1). About one-fifth of the sample (22%, 95% CI = 19.3–24.6) had taken some type 
of paracetamol combination product in the past week, with prescription only paracetamol/codeine 
combination products [contain ≥ 30 mg of codeine per tablet/unit (23)] the most commonly used 
paracetamol combination product (17%, 95% CI = 14.4– 
19.1) used. 
The mean daily paracetamol dose in the past week for all paracetamol users in the sample was 2501 
mg (SD 1470 mg) and 6.1% of paracetamol users (or 35 participants) had used more than 4000 
mg/day on average in the past week (Figure 2). The majority of participants who used paracetamol 
in the past week used an average of 3000 mg or less per day, with just under one-third of 
participants taking between 3001 and 4000 mg/day on average in the past week (31%, 95% CI = 
27.5–35.0). 
Forty-six participants (4.8%, 95% CI = 3.6–6.3) had taken greater than 4000 mg of paracetamol on at 
least 1 day in the last week and accounted for 8.0% of all paracetamol users (95% CI = 6.1–10.6). 
Within this group doses ranged from 0 mg to 9540 mg on any day in the last week, however, twenty-
four (52.0%, 95% CI = 38.1–65.9) of the forty-six participants had taken more than 4000 mg of 
paracetamol every day in the last week. The mean daily dose of paracetamol for those who had 
taken greater than 4000 mg on any day in the last week was 4616 mg (SD 1396 mg). 
Participants who had taken greater than 4000 mg on any day in the last week were compared with 
those who had taken paracetamol in the last week but did not exceed 4000 mg on any day (Table 3). 
Variables with a p-value less than 0.25 in the bivariate analysis as well as sex were included in the 
6 
 
Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol 
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J 
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text. 
 
multivariate binomial logistic regression model (age, income, mean pain severity, pain interference, 
relief from medications, paracetamol/opioid medication use, opioid dose, depression and pain self-
efficacy). Income, paracetamol/opioid combination product use and higher opioid dose were 
significantly associated with paracetamol use above 4000 mg on any day in the last week. The model 
was statistically significant (v2 = 25.98, df = 10, p = 0.004) and explained 11% (Nagelkerke R2) of the 
variance in paracetamol use above the recommended maximum daily dose. The model correctly 
classified 92.3% of cases, the sensitivity was 2.3% and the specificity was 100%, the positive 
predictive value was 100% and the negative predictive value was 92.2%. Participants with current 
income below $399/week had half the odds (Adjusted OR = 0.52, 95% CI = 0.27–0.99) compared to 
those with higher income of taking greater than 4000 mg of paracetamol on any day in the last 
week. Participants taking a paracetamol/opioid combination analgesics had twice the odds (Adjusted 
OR = 2.01, 95% CI = 1.02–4.00) compared to those who did not use combination analgesics of taking 
greater than 4000 mg of paracetamol on any day in the last week. Total opioid dose was also 
statistically significant in the multivariate model; however, the odds was only 1.003 (rounded to 
1.00, 95% CI = 1.00–1.01). A linearity assumption test confirmed that total opioid dose (as well as all 
the other 
 
Continuous variables in the model) is linearly related to paracetamol use above 4000 mg on any day 
in the past week. A graph of the log odds was also plotted against the range of total opioid dose 
(Figure 3). The graph illustrates that the log odds is linearly related and that the odds ratio is small 
because of a unit increase over the range of the continuous variable. The odds at the highest total 
opioid dose (800 mg/ day) in the sample increases to 2.4. Participants taking greater than 4000 mg 
of paracetamol on any day in the last week were more likely to have a higher total opioid dose. 
Figure 1 Paracetamol source according to the baseline self-report 1 week medication diary of people 
with chronic noncancer pain prescribed opioids from the pain and opioids in treatment (POINT) study. 
Paracetamol/codeine refers to nonprescription strength combinations (< 30 mg of codeine per 
tablet). Other prescription only paracetamol products included dextropropoxyphene/paracetamol 
and orphenadrine/paracetamol  
Figure 2 Mean daily paracetamol doses according to a self-report 1 week medication diary as a 
proportion of all paracetamol users in the pain and opioids in treatment (POINT) study 
Figure 3 Graph of the logistic regression log odds of the oral morphine equivelant daily dose (mg/day) 
in the past week and paracetamol use above reccomended maxinum daily doses (outcome) using the 
pain and opioids in treatment (POINT) study 
 
Discussion 
This is the first Australian study to examine use of paracetamol (acetaminophen) among a 
community sample of people with chronic non-cancer pain. The majority of participants had taken 
paracetamol in the last week and the most common paracetamol product used contained 
paracetamol as the only active ingredient, followed by prescription only paracetamol/codeine 
combination products. A minority had taken greater than 4000 mg on any day in the last week. 
Those exceeding the recommended maximum daily dose of paracetamol were more likely to have 
7 
 
Author postprint of Hoban, B., …, Hall, W., Farrell, M., & Degenhardt, L. (2015). The use of paracetamol 
(acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. Int J 
Clin Practice, 69, 1366-76. 10.1111/ijcp.12716. Please refer to published version for tables mentioned in the text. 
 
an income greater than $399/ week, to have taken paracetamol/opioid combination analgesics and 
to be taking a higher dose of opioids. 
The reported prevalence of paracetamol and non-opioid medication use above the recommended 
maximum daily dose varies in the literature from 3.4% to 14% (19,21,39), presumably as a result of 
different sampling frames and differing use of paracetamol/opioid combination products available in 
different countries (for example, paracetamol/hydrocodone is not available in Australia but is in the 
USA). Two US studies (19,39) reported the prevalence of paracetamol use above the recommended 
maximum daily dose (4.5% and 3.4%), whereas, a Belgian study (21) reported the prevalence of all 
medication use above recommended maximum daily doses (14%) in a cohort of people with CNCP. 
One of the US studies (19) examined paracetamol users whereas the other two studies (21,39) 
examined CNCP samples, however, the study on paracetamol users reported an association with 
CNCP. Although there are differences in the samples used in the literature and this study, they all 
identify a small group of people who use paracetamol or non-opioid medications above 
recommended maximum daily doses for CNCP. 
The association between use of paracetamol above the recommended maximum daily dose and use 
of paracetamol/opioid combination analgesics, appears to support previous studies that reported 
about onefifth of people who receive prescribed paracetamol/ opioid combination products are 
exceeding 4000 mg paracetamol per day (13). However, unlike the US studies, we do not know 
whether the scripts people were given exceeded 4000 mg/day or whether they took additional OTC 
paracetamol or extra prescribed paracetamol products to increase the daily dose above 4000 mg 
(13,18). While, the results of this study seem to support the FDA’s decision to decrease the dose in 
paracetamol/opioid combination products it must be stated that a 325 mg dose of paracetamol is 
sub-therapeutic and by using paracetamol and opioids separately, the doses can be titrated to an 
individual’s pain response. 
The association between use of paracetamol above the recommended maximum daily dose and 
higher total opioid dose although statistically significant in the multivariate model, did not appear to 
be clinically significant. However, the plot of the log odds demonstrated the unit increase associated 
with total opioid dose. This means that a single unit increase in total opioid dose (1 mg) does not 
have a clinically meaningful effect, however, a large increase does. The association between total 
opioid dose and paracetamol use above the recommended maximum daily dose is consistent with 
other study findings (13,15,21). This suggests that people who use paracetamol above the 
recommended maximum daily dose may be more reliant on medications to relieve their pain. 
Studies have reported that the majority of participants, who had used above the recommended 
maximum daily dose of paracetamol, did so to achieve adequate pain relief (40,41) and reviews on 
the effectiveness of opioid medications report only a modest level of pain relief (5–7). The 
association with higher opioid dose and paracetamol use above the recommended maximum daily 
dose suggests that there are a group of patients for which medications may not provide sufficient 
pain relief, and for whom other non-medication based treatments may be particularly important. 
This study is the first to find an association between use of paracetamol above the recommended 
maximum daily dose and income. This finding could be explained by differences in the healthcare 
system in Australia. The Australian healthcare system publicly subsidises prescriptions for some OTC-
strength analgesic medications (including some paracetamol products) to people who suffer from 
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chronic arthropathies (34) or if they have a healthcare card (given to low income earners who 
receive a government pension) (42). The cut-off for income used in this study (i.e., less than 
AUS$399/week) is approximately comparable with the income from unemployment or disability 
benefits. As a result, it is likely that there are more healthcare card holders among the lower income 
group, and medical practitioners and pharmacists may supervise paracetamol use more closely 
among this group. Unlike other studies (15,30), we did not find an association with smoking status at 
bivariate level, possibly because of a low smoking prevalence in Australia compared with that 
observed in different countries (33). 
This is the first Australian study of its scale to provide a context for paracetamol use in people living 
in the community with CNCP, reporting on a 1 week snapshot of medication use. As such, we do not 
know if the observed patterns are typical of paracetamol and opioid use over a longer time period. 
As the study has no measure of liver function, we also cannot comment on outcomes (such as 
hepatotoxicity) that may be important in better understanding adverse effects that may be 
associated with higher than recommended doses of paracetamol. However, a previous study in the 
USA on paracetamol/opioid combination prescriptions exceeding 4000 mg/day have indicated that a 
small proportion (n = 3818, 0.1%) of users developed liver dysfunction in the study period. Although 
this number is small, those who had a script exceeding 4000 mg/day of paracetamol accounted for 
23% (n = 894) of the sub-sample with liver dysfunction (13). In addition, it is possible that some 
participants were reluctant to disclose paracetamol use or daily dose; however, paracetamol use is 
not stigmatised like adherence to opioid treatment and all participants were informed that the 
interviews were confidential, de-identified and that their responses would not affect their medical 
treatment. Self-report of medication dose is subject to the possibility of recall bias (43); however, 
this is unlikely as participants were sent the diary before the interview and previous research on the 
topic has reported low rates of over reporting (1%) (44). In addition, self-report data are the best 
available data for this current study as patients’ prescribing records would not capture over the 
counter and/ or PRN medication use. The POINT study is a longitudinal study and in the future it may 
be possible to examine paracetamol use over a 24-month period and link use to adverse outcomes in 
linked data sets for the cohort. 
This study identified that a large proportion of people with CNCP prescribed opioids, use 
paracetamol (63%). Paracetamol as the only active ingredient was the most commonly used form of 
paracetamol (47%), followed by paracetamol/ codeine combination products (22%). While the 
majority of paracetamol users used less than 3000 mg of paracetamol per day, this study also 
identified a small group of people that were using paracetamol above the recommended maximum 
daily dose (4.8% of the sample or 8.0% or paracetamol users, used >4000 mg on at least 1 day in the 
past week). Those who had taken paracetamol above the recommended maximum daily dose were 
less likely to have a low income, more likely to have a higher total opioid dose and more likely to use 
a paracetamol/opioid combination analgesic. These findings have important clinical implications, 
namely that health professionals should actively question paracetamol use in people with CNCP 
prescribed opioids, particularly if they perceive their medication regime to be inadequate or use a 
paracetamol/opioid combination analgesic. 
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